192 results about "Cancer recurrence" patented technology

The subject disclosure presents systems and computer-implemented methods for assessing a risk of cancer recurrence in a patient based on a holistic integration of large amounts of prognostic information for said patient into a single comparative prognostic dataset. A risk classification system may be trained using the large amounts of information from a cohort of training slides from several patients, along with survival data for said patients. For example, a machine-learning-based binary classifier in the risk classification system may be trained using a set of granular image features computed from a plurality of slides corresponding to several cancer patients whose survival information is known and input into the system. The trained classifier may be used to classify image features from one or more test patients into a low-risk or high-risk group.

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

The present invention is directed to sensitive and specific methods and kits for the detection of prostate cancer in a patient. The invention uses RT-PCR to detect the expression or change in expression of PSA in epithelial cells enriched from whole blood. The methods and kits on the invention represent a a significant improvement over previous methods of CaP diagnosis. According to one embodiment, prostate epithelial cells are isolated from blood and the RNA subjected to RT-PCR. The resulting cDNA is subjected to traditional PCR amplification with primers able to distinguish between the genomic copy of the gene and the cDNA copy resulting from CaP gene expression. This method provides an assay which is more sensitive, specific and reproducible as compared to conventional methods. Results disclosed herein demonstrate a correlation between the presence of PSA-expressing prostate epithelial cells with cancer recurrence which provides a diagnostic tool for the early detection of prostate disease.

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.

The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.

The invention relates to a cancer recurrence prediction system based on a multi-dimensional Gaussian distribution Bayesian classification, which comprises a preprocessing module, a training module anda Bayesian classifier; the pre-processing module performs data cleaning on the training set and generates a class vector data set; the training module first calculates the first probability of two class attributes, and then divides the data attribute into a class data attribute set which is closely related to the class attribute and a class II data attribute set which is sparse with the class attribute association degree by using the pearson correlation coefficient, two types of data attribute sets are respectively used for calculating a corresponding probability by using a multi-dimensionalGaussian distribution and a one-dimensional Gaussian distribution; the Bayesian classifier combines both the probability of the two and the first probability of the class together as the probability of the data belonging to each class, and the classification test result of the cancer is judged accordingly. The cancer recurrence prediction system based on multi-dimensional Gaussian distribution Bayesian classification improves the predictive accuracy of the recurrence of the cancer.

An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.

Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.

The present invention is drawn to methods of assessing colorectal cancer prognosis by examining the expression of particular genes disregulated in this disease state. Subjects exhibiting disregulation in one or more of these genes will have a higher risk of cancer recurrence and death.

The invention discloses a gene group evaluating breast cancer molecule typing and a detection kit thereof. The gene group evaluating breast cancer molecule typing is a gene group composed of 216 genes. The invention also discloses the detection kit for the gene group evaluating breast cancer molecule typing. The detection kit comprises a primer capable of detecting the genes in the gene group for evaluating breast cancer molecule typing and cancer recurrence risk. An Illumina second-generation sequencing technology DASL-Seq is employed for detecting expression spectrum of cancer tissue, and on the above basis, breast cancer cases of Chinese women are divided into five molecule typing: 1) luminal type A, 2) luminal type B, 3) HER2 enrichment type, 4) basal cell type and 5) normal-cell like type, and propagation and immunization index are combined for calculating recurrence risk and pridicting recurrence possibility in 10 years, and thus individual treatment on breast cancer is guided.

The invention relates to a biomarker and detection method for detecting the risk of cancer recurrence, wherein the biomarker for detecting the risk of cancer recurrence comprises at least one of the following genes: SLCO2A1, CGNL1, SUPV3L1, TATDN2, MGAT4B, VAV2, SLC25A33, MCCC1, ASNS, CASKIN1, DNMT3B, AURKA, OIP5, CTHRC1 and GOLGA7B. The biomarker for detecting the risk of cancer recurrence, provided by the invention, has an advantage of effectively predicting the recurrence risk of cancers such as prostate cancer and the like.

The invention discloses a biopolymer pharmaceutical composition for tumor therapy. The biopolymer pharmaceutical composition comprises a first component and a third component, wherein the first component is alginate; the alginate can form porous gel together with calcium ions in vivo, and the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate; and the third component is an immune adjuvant. The biopolymer pharmaceutical composition can generate a synergistic anti-cancer effect, and reduces side effects, the cancer metastasis probability, and the cancer recurrence probability.

A method of determining likelihood of acquiring drug resistance of a tumor or cancerous cells, cancer metastasis, cancer recurrence, or decreased life expectancy, comprising measuring the level of MUC1 or MUC1-associated factor expressed in the cancerous cells or tumor.

The present invention discloses a breast cancer treatment traditional Chinese medicine, and belongs to the field of traditional Chinese medicines. The breast cancer treatment traditional Chinese medicine is prepared from the following raw materials: 20 g of trichosanthes kirilowii maxim, 20 g of milkvetch root, 20 g of common selfheal spike, 20 g of oyster, 15 g of bupleurum chinense, 15 g of scutellaria baicalensis georgi, 15 g of curcuma aromatica salisb., 15 g of angelica, 15 g of immature tangerine fruit, 15 g of white peony root, 15 g of balloonflower root, 15 g of szechwan lovage rhizome, 10 g of bulbus fritillariae cirrhosae, 10 g of dandelion, 10 g of stiff silkworm, 10 g of ginseng, 10 g of fructus aurantii, 10 g of magnolia officinalis, 10 g of angelica archang lica, 10 g of saposhnikovia divaricata, 10 g of lindera aggregata, 10 g of pangolin, 6 g of tangerine peel, 6 g of akabia stem, and 6 g of licorice root. The breast cancer treatment traditional Chinese medicine has effects of healthy energy supporting, qi reinforcing, blood nourishing, spleen strengthening, liver soothing, blood stasis dissipating, detoxication, good chemotherapy reaction alleviating and cancer recurrence and metastasis prevention so as to increase the comprehensive treatment effect and achieve the purposes of patient symptom improvement and complete cancer cell killing.

A N1-cyclic amine-N5-substituted biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.